In preclinical trials on mice,

400 percent greater levels of the cancer drug, 5-FU, effectively targeted

tumors in mice injected with Davanat-1. Since the healthy cells were left

alone, side effects -- such as nausea, hair loss, and fatigue were minimal.

Human trials of the drug started

this past February at four sites: Dartmouth-Hitchcock in Lebanon, N.H.,

the University of Michigan, Ann Arbor, Ochsner Cancer Institute in New

Orleans and Florida Oncology Associates in Jacksonville, Fla. All of the

patients invited to participate are considered refractory patients -

meaning this is their last hope. They are in advanced stages of cancer

and conventional treatments - radiation, surgery and chemotherapy

alone - have failed them.

"If the preclinical trial

results are any indication, we may have a lot of miracles in the works,"

said Dr. Platt. "Of the mice injected only with 5-FU, 65 percent

died. We had a 100-percent survival rate for mice that received Davant-1."

"The treatment sounds

very promising," said Dr. Bone. "I'm looking forward to

seeing the results of the human trials."

Once the results of the Phase

l human trials are reported, sometime next year, to the Food and Drug

Administration, the FDA will decide whether DAVANAT-1 should be added

to the arsenal of cancer fighting drugs.

For more details about the

study, log onto www.pro-pharmaceuticals.com or www.clinicaltrials.gov

(keyword: DAVANAT).

Back

to Healthwise Home Page |